This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (15)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

DONALD C. ABELE, M.D.; RICHARD L. DOBSON, M.D.

Arch Dermatol. 1960;82(5):725-731.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In 1948, Gomori¹ reported increased amounts of phosphamidase in malignant tissue. This observation implied that it might be possible to synthesize a phosphamide ester of nitrogen mustard which could be converted to an active cytotoxic form within malignant tissue. Theoretically, such a compound would show cytotoxic activity only, or at least maximally, within the abnormal tissue cells. A compound with these properties was produced in 1957 by Arnold, Bourseaux, and Brock.² This compound has the structure shown in Figure 1.

This agent has been used in the therapy of various solid tumors and hematologic malignancies with varying success. Preliminary observations on animal and human studies of the drug have been summarized by Lane,³ Venditti, Humphreys, and Goldin,⁴ and Coggins, Ravdin, and Eisman.⁵

Because of the theoretical advantages of such an agent, an evaluation of the usefulness of cyclophosphamide (Cytoxan) in the therapy of mycosis fungoides . . . [Full Text PDF of this Article]

Author Affiliations
Chapel Hill, N.C.

Division of Dermatology, Department of Medicine, University of North Carolina School of Medicine.

Footnotes
Submitted for publication April 18, 1960.

Cytoxan supplied through the courtesy of Dr. Willard Nicholl, Mead, Johnson & Company.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?